Sorry, you need to enable JavaScript to visit this website.

RETACRIT™ (epoetin alfa-epbx) Patient Counseling Information

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Inform patients:

  • Of the increased risks of mortality, serious cardiovascular reactions, thromboembolic reactions, stroke, and tumor progression [see Warnings and Precautions (5.1, 5.2)].
  • To undergo regular blood pressure monitoring, adhere to prescribed anti-hypertensive regimen and follow recommended dietary restrictions.
  • To contact their healthcare provider for new-onset neurologic symptoms or change in seizure frequency.
  • Of the need to have regular laboratory tests for hemoglobin.
  • Risks are associated with benzyl alcohol in neonates, infants, pregnant women, and lactating women [see Use in Specific Populations (8.1, 8.2, 8.4)].

Instruct patients who self-administer RETACRIT of the:

  • Importance of following the Instructions for Use.
  • Dangers of reusing needles, syringes, or unused portions of single-dose vials.
  • Proper disposal of used syringes, needles, and unused vials, and of the full container.

What's New

No Current Announcements.

Contact Pfizer Medical

Search

Please enter your search term(s) for RETACRIT™